Medtronic Inc (MDT) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Medtronic Inc (MDT)

90.65

-0.58 (0.64%)

as of Aug 31, 2026, 8:00:00 pm Market Open.

183 watching

Investor Insights

Aug 31, 2026, 12:00 am

This summary was created by AI, based on 4 opinions in the last 12 months.

Medtronic Inc (MDT) is viewed positively by various experts, benefiting from demographic tailwinds as the aging Baby Boomer population becomes a relevant customer base. The company is currently trading at a price-to-earnings (PE) ratio of 15x, complemented by a solid 7% free cash flow yield and anticipated earnings growth of 8-9% over the next several years. Recent momentum has seen the stock rise 20% in the past three months, suggesting strong market interest as it approaches its upcoming earnings report. Despite competition, particularly from Boston Scientific, Medtronic's diversified portfolio sets it apart from peers who may lack similar R&D capabilities. While short- to medium-term outlook is optimistic, some experts caution against viewing Medtronic as a long-term investment due to potential challenges in maintaining leadership and innovation in the industry.

Consensus

Positive

Valuation

Undervalued

Similar

Stryker,SYK

BUY

Likes med-tech space. Space has historically traded at 20 PE’s and up. Growth is very good. Demographics are very positive. Currently out of favour because of fears of what the government will do to the industry. Trading at one of the lowest multiples in its 20-year history.

TOP PICK

Model $42.48.

TOP PICK

He has a model price of $41.29 giving it a 21% positive differential. Just reported greater earnings. 2% yield.

BUY

Likes medical devices sector. Of all the sectors, medical equipment is one of the tops. Regardless of what is going on in the economies , medical devices will continue to sell. He owns Zoll Medical (ZOLL-Q) instead, which has more growth potential. Thinks there is more upside potential in the small/mid-cap size names.

BUY

PE of about 20 and anticipated growth rate of about 14%. Have a lot of intellectual property. Reasonably attractive.

DON'T BUY

His model price is $41.45 so it is a negative 23%-24% differential. This is one of those stocks that is perpetually overvalued.

BUY

Likes a lot of the big US healthcare stocks. Valuation is reasonable.

BUY ON WEAKNESS

On his watch list as a possible investment. Valuation has been hurt but the fundamentals have not changed much. The long-term outlook for their products is very good.

Wealthica Track your Stocks in your Watch List

TOP PICK

A high quality, growth company. Good price. The leading medical technology company in the world.

TOP PICK

Solid earnings. Feels their new stent will be successful next year.

DON'T BUY

Interesting company. Market is very strong for their products. Stock isn't cheap. Has been growing slowely

DON'T BUY

Valuation is a little bit ahead of the stock. Very good management.

DON'T BUY

Competition. Too expensive at 30 X earnings.

BUY ON WEAKNESS

Great company. Buy in the mid to low $20's.

TOP PICK

Good company. Not a cheap stock. A cash machine.

Showing 106 to 120 of 127 entries

Most Recent Experts

Andrey Omelchak

LionGuard Capital Management

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Capital Wealth Planning

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Medtronic Inc (MDT)